GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action lawsuit in the U.S. District Court for the Eastern District of Pennsylvania alleging ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...